Develops and characterizes injectable collagen-chitosan hydrogels with varying thymosin β4 loading for intramyocardial delivery after MI. Hydrogel formulations were optimized for injectability, mechanical properties matching cardiac tissue, and sustained TB4 release kinetics. In vitro testing confirmed biocompatibility and cardiomyocyte-protective activity. Provides a biomaterial scaffold for local cardiac TB4 delivery—addressing systemic TB4's short half-life by creating a depot formulation that maintains therapeutic concentrations at the infarcted myocardium.
Shaghiera, Achmad Dzihan; Widiyanti, Prihartini; Yusuf, Helmy